List of Excipients in Branded Drug HIBISTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mölnlycke Health Care US LLC	HIBISTAT	chlorhexidine gluconate and isopropyl alcohol	0234-0587	CASTOR OIL
Mölnlycke Health Care US LLC	HIBISTAT	chlorhexidine gluconate and isopropyl alcohol	0234-0587	GLYCERIN
Mölnlycke Health Care US LLC	HIBISTAT	chlorhexidine gluconate and isopropyl alcohol	0234-0587	WATER

HIBISTAT Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

HIBISTAT is a topical antiseptic based on chlorhexidine gluconate and isopropyl alcohol. Its commercial value depends less on a novel active ingredient than on formulation performance, skin tolerability, packaging compatibility, regulatory positioning, and supply reliability. The strongest opportunities are in differentiated hand antisepsis, healthcare-use packaging, lower-irritancy systems, and institutional supply contracts.

What is the HIBISTAT formulation?

HIBISTAT is generally identified as an antiseptic formulation containing 0.5% chlorhexidine gluconate in 70% isopropyl alcohol. The product is intended for topical antiseptic use, including healthcare hand antisepsis and preparation of intact skin, subject to the applicable product labeling and FDA regulatory status. [1]

Formulation element	Commercial function	Primary development issue
Chlorhexidine gluconate	Persistent antimicrobial activity	Compatibility, skin sensitization, stability
Isopropyl alcohol	Rapid antimicrobial kill and fast drying	Flammability, drying, irritation
Purified water	Solvent and concentration control	Microbial quality and alcohol-content control
Humectant or emollient, if present	Reduces skin dryness	Can slow drying or affect antimicrobial performance
Surfactant or solubilizer, if present	Improves wetting and uniformity	May increase irritation or reduce preservative margin
Packaging components	Dispensing, containment, user safety	Alcohol permeation, stress cracking, extractables

HIBISTAT’s excipient strategy must preserve the balance between rapid drying, immediate antimicrobial activity, residual chlorhexidine effect, and acceptable skin feel. A formulation that improves moisturization but leaves a sticky residue may be less acceptable in operating rooms or high-throughput clinical environments.

Which excipients are most important for HIBISTAT?

Humectants and emollients

Humectants such as glycerin, propylene glycol, or selected glycols can reduce the defatting effect of isopropyl alcohol. They may improve repeated-use tolerability, a key purchasing criterion for hospitals and healthcare workers.

Their use has limits. Higher concentrations can:

• Increase drying time.
• Produce tackiness.
• Reduce user acceptance.
• Affect spray or pump delivery.
• Change the evaporation profile.
• Interact with chlorhexidine or packaging materials.

Glycerin is commercially familiar and generally easy to source, but a low-viscosity system may be preferable for fast application and rapid drying. Propylene glycol can provide both humectancy and solvent activity, but it can create a heavier skin feel and may require more extensive irritation testing.

Water content

Water affects chlorhexidine solubility, alcohol evaporation, skin feel, and microbial performance. The formulation should control water activity and alcohol concentration within the registered specification. Small changes can affect:

• Antimicrobial kill time.
• Drying speed.
• Viscosity.
• Container closure integrity.
• Flammability classification.
• Batch-to-batch consistency.

Water quality should be managed under applicable pharmaceutical or cosmetic water standards, depending on the regulatory pathway and manufacturing site. [2]

Surfactants and solubilizers

Surfactants can improve wetting of the skin and help maintain uniformity. Their use is commercially relevant for foams, wipes, and nontraditional delivery systems.

Potential candidates include nonionic surfactants and carefully selected solubilizers. The development risk is that surfactants can:

• Increase irritation.
• Alter chlorhexidine availability.
• Reduce residual activity.
• Generate foam that slows drying.
• Complicate preservative and microbial limits.

Chlorhexidine is cationic. Anionic excipients and some anionic surfactants can create compatibility problems or reduce antimicrobial activity. This is a core formulation constraint. Excipient selection should therefore prioritize nonionic or otherwise demonstrably compatible materials.

Chelating agents and antioxidants

Chelating agents can affect trace-metal control and formulation stability, but their role must be evaluated against chlorhexidine compatibility. Antioxidants are less central than in oxygen-sensitive products because the main actives are not typically managed through a conventional oxidation-control strategy. Their inclusion should be justified by stability data rather than used as a default excipient approach.

How should an improved HIBISTAT formulation be designed?

A commercially credible development program should compare at least three platforms:

Platform	Primary benefit	Main risk	Commercial use
Standard hydroalcoholic liquid	Fast drying and simple manufacturing	Skin dryness and flammability	Bottles, pump dispensers
Moisturizing liquid	Better repeated-use tolerability	Slower drying and residue	Hospitals and outpatient clinics
Foam or gel	Controlled dosing and reduced splashing	Delivery-system and compatibility risk	Point-of-care stations
Impregnated wipe	Portability and controlled application	Dry-out, uniformity, packaging cost	Emergency, travel, procedure kits

The baseline comparator should remain the conventional 0.5% chlorhexidine gluconate and 70% isopropyl alcohol system. Any excipient change should be evaluated against the comparator for antimicrobial activity, residual effect, drying time, hand-feel, flammability, container compatibility, and repeated-use irritation.

The most defensible product profile is a low-residue, fast-drying liquid with modest humectant content. A highly viscous gel may offer stronger differentiation but could move the product away from the use pattern associated with traditional HIBISTAT.

What formulation patents could protect HIBISTAT improvements?

The active combination is likely to have limited value as a standalone composition claim because chlorhexidine and alcohol antiseptic systems are established technologies. New intellectual-property value would more likely come from narrow formulation, delivery, packaging, or manufacturing claims.

Potential claim areas

1. Low-irritation hydroalcoholic formulation
   Claims could cover specified concentrations of chlorhexidine gluconate, isopropyl alcohol, water, and humectant, combined with defined skin-tolerability or drying parameters.

2. Foam or gel delivery system
   Protection could focus on viscosity, foam density, dispensing dose, drying time, or pump architecture.

3. Compatibility-controlled formulation
   A claim could address exclusion of anionic excipients, control of pH, or maintenance of chlorhexidine concentration during shelf life.

4. Impregnated wipe
   Patentable features could include substrate composition, liquid loading, package design, evaporation control, and uniformity of active delivery.

5. Packaging and dispensing
   Potential protection includes alcohol-resistant plastics, pressure-sensitive valves, tamper evidence, spill prevention, and metered dosing.

6. Manufacturing process
   Process claims could cover order of addition, mixing conditions, filtration, filling, or controls that reduce precipitation and concentration variability.

Patent strength would depend on claim breadth, prior-art proximity, enablement, and the ability of competitors to design around the claimed excipient ranges. A narrow claim covering a specific humectant concentration may be commercially useful but vulnerable to substitution with another compatible moisturizer.

When does HIBISTAT lose exclusivity?

HIBISTAT does not obtain meaningful market exclusivity merely from using a known antiseptic combination. Exclusivity depends on the applicable regulatory pathway, trademark rights, formulation patents, method-of-use patents, and any current FDA-listed marketing status.

Exclusivity mechanism	Relevance to HIBISTAT
New-drug patent protection	Relevant only if a valid, enforceable patent covers a novel formulation or use
OTC monograph pathway	Usually limits reliance on brand-based exclusivity
Trademark protection	Protects the HIBISTAT name, not the formulation
Formulation patent	Could delay or complicate competing products
Method-of-use patent	Potentially relevant for specific antiseptic procedures
Orphan or biologic exclusivity	Not applicable to this small-molecule topical antiseptic
Pediatric exclusivity	Product-specific and not inherent in the brand
Data exclusivity	Depends on the approved regulatory pathway and product history

A competitor could potentially enter with a chlorhexidine-alcohol product under a different brand if it satisfies applicable FDA requirements and avoids valid patent claims. The principal barriers are regulatory compliance, clinical or performance substantiation, manufacturing controls, and institutional purchasing qualification.

What is the FDA regulatory status of HIBISTAT?

HIBISTAT is a topical antiseptic product, not a biologic. Its regulatory analysis should distinguish the marketed product’s specific NDC and labeling from the broader FDA framework for topical antiseptic drugs.

FDA’s topical antiseptic framework has evolved through rulemaking, monograph activity, and safety-data requirements. Alcohol-based antiseptics and chlorhexidine products have been subject to FDA scrutiny concerning antimicrobial effectiveness, systemic exposure, and safety. [3] Chlorhexidine-containing products also carry important warnings regarding serious allergic reactions, including anaphylaxis. [1,4]

The regulatory priorities for a reformulated HIBISTAT product would include:

• Confirmation of active-ingredient eligibility.
• Qualification of excipients for the route and concentration.
• Antimicrobial effectiveness.
• Stability and impurity control.
• Skin irritation and sensitization.
• Container-closure integrity.
• Flammability and transportation compliance.
• Labeling for external use and eye or mucosal exposure.
• Manufacturing under applicable current good manufacturing practice requirements.

A changed excipient system may require more than a simple formulation update if it changes dosage form, delivery mechanism, claims, antimicrobial performance, or safety profile.

Does HIBISTAT have Orange Book protection?

Orange Book status is product-specific. A reliable conclusion requires confirmation of the current FDA listing for the relevant HIBISTAT NDC, application number, and approved labeling. The presence of a brand name does not establish that the product has listed patents or that an ANDA pathway is available.

For an Orange Book assessment, the relevant questions are:

• Is HIBISTAT associated with an approved NDA?
• Are patents listed for the specific approved product?
• Is the listed product marketed, discontinued, or withdrawn?
• Does the proposed competitor qualify as an ANDA product?
• Would the competitor need a 505(b)(2) application because of formulation or clinical differences?

If no relevant listed patent exists, a competitor may face fewer Paragraph IV barriers, but it would still need to satisfy the applicable FDA route and demonstrate product quality and performance.

Are Paragraph IV challenges or biosimilar risks relevant?

A biosimilar challenge is not relevant because HIBISTAT is a nonbiologic topical antiseptic. Paragraph IV risk is relevant only if an approved NDA has patents listed in the Orange Book and a generic applicant files an ANDA with a Paragraph IV certification.

The likely competitive routes are:

• An ANDA for a pharmaceutically equivalent product.
• A 505(b)(2) application for a materially different formulation or delivery system.
• An OTC monograph-compliant product, if the regulatory conditions permit that route.
• A private-label or institutional product using a noninfringing formulation.

The commercial risk is highest when the proposed product closely copies the reference formulation but has no difficult-to-design-around excipient, delivery, or packaging feature.

What commercial opportunities exist for HIBISTAT excipients?

Hospital and healthcare-worker market

The strongest opportunity is repeated-use hand antisepsis. Hospitals may value reduced skin irritation, reliable dose delivery, and compatibility with wall-mounted dispensers more than a marginal increase in antimicrobial performance.

An improved HIBISTAT platform could target:

• Operating rooms.
• Intensive-care units.
• Emergency departments.
• Dental practices.
• Long-term-care facilities.
• Home-health providers.
• Ambulance and emergency-response kits.

Private-label and contract manufacturing

A validated excipient system could support private-label supply agreements. The manufacturer could offer the same base formulation in multiple package sizes and delivery formats, reducing development and manufacturing complexity.

Potential formats include:

• 30 mL and 60 mL bottles.
• 100 mL and 500 mL pump containers.
• Wall-mounted refill cartridges.
• Single-use sachets.
• Procedure kits.
• Impregnated wipes.

International markets

Geographic expansion may be attractive, but antiseptic registration, labeling, alcohol classification, and permitted claims vary by jurisdiction. The European Union, United Kingdom, Canada, Australia, and emerging markets may apply different requirements to chlorhexidine-alcohol products, biocidal products, medicinal products, or medical-device accessories.

A global formulation should minimize jurisdiction-specific excipient changes. Packaging and labeling may require more adaptation than the liquid composition.

How strong is the patent estate for HIBISTAT?

The likely strength of a HIBISTAT patent estate depends on whether it includes product-specific formulation patents rather than only trademark protection or broad claims to known antiseptic ingredients.

Patent category	Expected strategic value
Broad chlorhexidine-alcohol composition	Low, due to established prior art
Specific low-irritation excipient range	Moderate if supported by comparative data
Foam or gel delivery system	Moderate to high if technically distinctive
Wipe substrate and packaging	Moderate
Metered dispenser	Moderate, with design-around risk
Manufacturing process	Moderate if process controls produce a measurable advantage
Method of use	Variable and dependent on claim scope
Trademark	High brand value, but no formulation exclusivity

The strongest portfolio would combine formulation claims with packaging, dispensing, and manufacturing claims. Each category should be drafted around measurable technical outcomes, such as drying time, chlorhexidine stability, dose uniformity, microbial reduction, or reduced irritation.

What generic launch scenarios exist for HIBISTAT?

Scenario 1: Direct liquid competitor

A competitor launches a 0.5% chlorhexidine gluconate and 70% isopropyl alcohol liquid in comparable packaging. Price competition and institutional contracting would be the main risks.

Scenario 2: Moisturizing substitute

A competitor uses a different humectant or emollient to improve skin tolerability. This scenario creates limited freedom-to-operate risk unless the HIBISTAT patent claims cover a broad functional formulation range.

Scenario 3: Foam or gel substitute

A competitor markets a different dosage form. This product may avoid composition claims but compete for the same hand-antisepsis budget.

Scenario 4: Wipe-based product

A wipe could gain share in emergency, travel, and procedure-kit settings. Its principal advantages would be portability and controlled application rather than lower unit cost.

Scenario 5: Institutional private label

A hospital distributor or contract manufacturer could replace the branded product with a private-label equivalent. Brand loyalty would offer limited protection if procurement decisions are driven by price, dispenser compatibility, and supply continuity.

Key Takeaways

• HIBISTAT’s core formulation is a chlorhexidine gluconate and isopropyl alcohol antiseptic system.
• The most valuable excipient opportunities involve skin tolerability, drying time, residue control, and delivery consistency.
• Nonionic and chlorhexidine-compatible excipients are preferred over potentially reactive anionic materials.
• Foam, gel, wipe, packaging, and metered-dosing systems provide stronger differentiation than a simple ingredient substitution.
• HIBISTAT is not exposed to biosimilar competition.
• Generic and private-label competition could be significant if no enforceable product-specific patents block entry.
• Orange Book and Paragraph IV conclusions require product-specific FDA listing analysis.
• A commercially effective patent portfolio would combine formulation, packaging, dispensing, and manufacturing claims.
• Institutional contracts and private-label supply are likely to be more important than consumer brand premiums.
• Regulatory, flammability, packaging, and chlorhexidine-safety requirements are central to commercialization.

FAQs

Can glycerin be added to HIBISTAT?

Glycerin may improve skin feel, but its concentration must be optimized against drying time, residue, antimicrobial performance, stability, and dispenser behavior.

Is a gel formulation commercially better than the HIBISTAT liquid?

Not necessarily. A gel may improve dosing control and reduce splashing, but it can dry more slowly and create a different user experience. The best format depends on the target setting.

Can a competitor avoid HIBISTAT patents by changing the humectant?

Often, yes, if protection is limited to a named excipient or narrow concentration range. Broader functional claims may create greater design-around difficulty, subject to validity and enforceability.

Are chlorhexidine and alcohol compatible in the same formulation?

They can be combined, as demonstrated by established antiseptic products, but stability, concentration control, excipient compatibility, and packaging performance require product-specific validation.

What is the most defensible commercial improvement to HIBISTAT?

A fast-drying, low-residue formulation with improved repeated-use skin tolerability and validated compatibility with hospital dispensing systems offers the clearest combination of clinical utility and commercial differentiation.

References

1. DailyMed. (n.d.). Hibistat: Chlorhexidine gluconate and isopropyl alcohol topical solution labeling. U.S. National Library of Medicine.

2. United States Pharmacopeia. (2023). General chapter <1231>: Water for pharmaceutical purposes. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). OTC topical antiseptic drug products and related rulemaking materials. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2017). FDA warns about rare but serious allergic reactions with chlorhexidine gluconate. U.S. Department of Health and Human Services.